Avacta signs diagnostic licensing deal with Biokit
Avacta Group, the developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has entered into a license agreement with Biokit, a Werfen Company, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product.
